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Abstract
Rationale Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psyche-
delics have recently reemerged as a potential therapeutic treatment option.
Objective We present the first meta-analytic review evaluating the clinical effects of classic serotonergic psychedelics vs placebo
for mood state and symptoms of depression in both healthy and clinical populations (separately).
Results Our search revealed 12 eligible studies (n = 257; 124 healthy participants, and 133 patients with mood disorders), with
data from randomized controlled trials involving psilocybin (n = 8), lysergic acid diethylamide ([LSD]; n = 3), and ayahuasca
(n = 1). The meta-analyses of acute mood outcomes (3 h to 1 day after treatment) for healthy volunteers and patients revealed
improvements with moderate significant effect sizes in favor of psychedelics, as well as for the longer-term (16 to 60 days after
treatments) mood state of patients. For patients with mood disorder, significant effect sizes were detected on the acute, medium
(2–7 days after treatment), and longer-term outcomes favoring psychedelics on the reduction of depressive symptoms.
Conclusion Despite the concerns over unblinding and expectancy, the strength of the effect sizes, fast onset, and enduring
therapeutic effects of these psychotherapeutic agents encourage further double-blind, placebo-controlled clinical trials assessing
them for management of negative mood and depressive symptoms.
Keywords Depression . Psilocybin . Ayahuasca . LSD .Mescaline . Placebo
Introduction
Overview
There is currently a resurgence of research investigating the
use of psychedelic substances in the treatment of mood disor-
ders, mainly the “classic serotonergic psychedelics” (Chi and
Gold 2020; Dos Santos et al. 2018; Reiff et al. 2020;
Schenberg 2018). This class of psychedelics includes psilocy-
bin, dimethyltryptamine ([DMT], often consumed via the tra-
ditional plant preparation ayahuasca), lysergic acid
diethylamide (LSD), and mescaline. These substances may
induce psychedelics effects as potential agonists of the sero-
tonin 2A receptors. Although it is recognized, they may also
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interact to a lesser extent with other neurotransmitter path-
ways, such as partial agonism of the serotonin 2C receptors,
through which they may also induce antidepressant activity
(Araujo et al. 2015; Baumeister et al. 2014; Halberstadt and
Geyer 2011).
One factor contributing to this resurgence is the limited
success of existing pharmacotherapies for patients with de-
pressive disorders (Thase et al. 2001). Many antidepressants
may have a long latency to therapeutic response, requiring two
to 6 weeks to produce effects, and can potentially induce un-
desirable side-effects, resulting in increased patient distress or
discontinuation of treatment (Blier and de Montigny 1994;
Carvalho et al. 2016; Posternak and Zimmerman 2005). A
substantial portion of depressed patients do not benefit sub-
stantially from antidepressant treatment, (Cipriani et al. 2018;
Hengartner and Plöderl 2018; Kirsch 2014; Munkholm et al.
2019; Thase et al. 2001). As a result, up to half of patients with
depression may develop treatment-resistant disorders, defined
as a failure to achieve remission with two or more adequate
antidepressant trials (Akil et al. 2018; Conway et al. 2017).
Given the scale and impact of this problem, innovative
treatment approaches for major depression are urgently need-
ed, and it is in this context that there has been renewed clinical
and research interest in the classic serotonergic psychedelics
(Dos Santos et al. 2018; Schenberg 2018). In general, seroto-
nergic psychedelics do not lead to withdrawal or compulsive
drug-seeking behaviors, as are observed with substances such
as opioids and cocaine (Bogenschutz and Johnson 2016;
McKenna 2004). They are generally considered safe and do
not induce physiological toxicity or lasting adverse effects,
although transitory signs of cognitive and emotional alter-
ations, and mild sympathetic activity, are common
(Bogenschutz and Ross 2018). Studies examining data from
the National Survey on Drug Use and Health (2001–2004) in
the USA have reported no significant associations between
lifetime psychedelic use and adverse mental health outcomes,
including psychosis, with some evidence of reduced risk of
these outcomes (Johansen and Krebs 2015; Krebs and
Johansen 2013). However, restrictions on the use of psyche-
delics are indicated for individuals with severe cardiac disease
and either a personal or family history of psychosis.
Therefore, the classic psychedelics are again being utilized
in pre-clinical, observational, open-label, and randomized con-
trolled trials examining effects on mood in psychiatry patients
and healthy volunteers, with highly encouraging initial results
being reported (Carhart-Harris et al. 2016b; Dolder et al. 2016;
Dos Santos et al. 2011; Hasler et al. 2004; Kometer et al. 2012;
Kraehenmann et al. 2015; Osorio Fde et al. 2015; Palhano-
Fontes et al. 2019; Ross et al. 2016; Schmid et al. 2015;
Schmid and Liechti 2018; Wittmann et al. 2007). Mescaline,
usually derived from the peyote cactus (Bogenschutz and Ross
2018; Heffter 1898), and LSD were investigated in older psy-
chiatric studies, conducted to explore effects on psychosis and
alcoholism (Berlin et al. 1955; Blum et al. 1977; Fuentes et al.
2019; Gouzoulis-Mayfrank et al. 1998; Hofmann 1979; Krebs
and Johansen 2012; Pahnke et al. 1970; Rucker et al. 2018).
More recently, LSD studies have turned to the investigation of
its effect on mood (Carhart-Harris et al. 2016b; Dolder et al.
2016; Gasser et al. 2014; Gasser et al. 2015; Schmid et al. 2015;
Schmid and Liechti 2018).
The current second wave of psychedelic research has pri-
marily involved psilocybin, the main psychedelic compound
of Psilocybe spp. fungi (Rucker et al. 2018). Open-label trials
have been conducted in obsessive-compulsive disorder
(Ballenger 2008; Moreno et al . 2006), addiction
(Bogenschutz et al. 2015; Johnson et al. 2014), and
treatment-resistant depression (Carhart-Harris et al. 2016a;
Carhart-Harris et al. 2017), whereas double-blind trials have
been conducted in patients with life-threatening cancer diag-
noses (commonly exploring effects on mood and existential
anxiety) (Griffiths et al. 2016; Griffiths et al. 2006; Grob et al.
2011; Hasler et al. 2004; Kometer et al. 2012; Kraehenmann
et al. 2015; Ross et al. 2016; Wittmann et al. 2007). On the
strength of this evidence, the United States Food and Drug
Administration granted “breakthrough therapy” status to psi-
locybin in 2019, concluding that initial data indicate that it
may provide a substantial improvement over existing treat-
ments for treatment-resistant depression (Pathways 2018).
Ayahuasca is an Amazonian brew made with Psychotria
viridis, a rubacea containing N, N-DMT, and Banisteriopsis
caapi, a vine which contains β-carbolines that are reversible
inhibitors of monoamine oxidase and an inhibitor of serotonin
reuptake (Palhano-Fontes et al. 2014). This psychedelic also
has been subject to increasing research, which has included
effects on mood and addiction in healthy volunteers
(McKenna 2004; Riba et al. 2001; Santos et al. 2007; Uthaug
et al. 2018), as well as clinical trials investigating its psycho-
logical and neurobiological antidepressant effects in open-label
and double-blind designs (de Almeida et al. 2019; Dos Santos
et al. 2011; Galvão et al. 2018; Osorio Fde et al. 2015; Palhano-
Fontes et al. 2019; Zeifman et al. 2019).
Aims and objective
As a consequence of the expanding number of clinical studies
investigating psychedelic treatments for psychiatric disorders,
the number of reviews on this topic has also increased in
recent years (Bogenschutz and Ross 2018; Chi and Gold
2020; Dos Santos et al. 2018; Johnson et al. 2019; Muttoni
et al. 2019; Ross 2018; Rucker et al. 2018). A recent meta-
analysis review showed that psychedelic-assisted therapy,
which included both the classic serotonergic psychedelics
and MDMA (3,4-methylenedioxymethamphetamine), signif-
icantly outperformed placebo, with large effect sizes across a
range of mental disorders such as unipolar depression, anxi-
ety, and post-traumatic stress disorder (Luoma et al. 2020).
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However, to date, no meta-analysis of double-blind random-
ized controlled trials (RCTs) comparing the clinical efficacy
of classic serotonergic psychedelics with placebo, for mood
and depressive symptoms, has been published. Our aim is to
present the first meta-analysis in this area, by evaluating the
clinical effect of classic serotonergic psychedelics on negative
mood state and depressive symptoms, in double-blind RCTs,
separately for both healthy volunteers and patients diagnosed
with a mood disorder.
Methods
The search strategy and data synthesis were conducted in line
with the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement (Moher et al.
2009) and followed a registered protocol (PROSPERO regis-
tration number: CRD42020158356).
Systematic search
The systematic search was conducted using the Cochrane
Central Register of Controlled Trials, Cochrane Database of
Systematic Reviews, Health Technology Assessment
Database, Allied and Complementary Medicine, PsycINFO,
and Ovid MEDLINE(R), from journal inception to May,
2020. A search via Web of Science was conducted using the
same keywords to identify any additional relevant articles.
Reference lists of included articles were also searched.
During the initial screening, 4 raters (NLGC, MG, JS, and
MM) independently assessed articles retrieved for eligibility
based on the title, abstract, and in method, after which full text
articles were retrieved and screened.
Eligibility criteria
Eligibility criteria were organized in accordance with the
PICO (participants, interventions, comparisons, and out-
comes) reporting structure, as described below. The search
terms used in systematic review search are summarized in
Table 1.
Participants
After a systematic search of the relevant data, we included
studies with both healthy individuals and patients with mood
disorders who were diagnosed using the Diagnostic and
Statistical Manual of Mental Disorders IV (DSM-IV)
(Table 1). The data for patients with a mood disorder and
healthy participants were analyzed separately to avoid conflat-
ing heterogeneous populations.
Interventions
All classic serotonergic psychedelic interventions were in-
cluded: mescaline, LSD, DMT/Ayahuasca, and psilocybin.
However, after a systematic search, we included studies that
investigated psychedelic interventions using the “psychedelic
model,” where interventions were provided to participants in
moderate to high doses in single or multiple sessions (Reiff
et al. 2020; Ross 2012). Studies using micro-doses and low
doses of psychedelics (e.g., for psilocybin below 100 μg/kg)
(Hasler et al. 2004) were excluded.
Comparation
All studies included were randomized, placebo-controlled,
and double-blind trials, which had either a cross-over or par-
allel design, with outcomes between 3 h and 60 days after
dosing session (see below the “Outcomes” section for more
details). Control groups must have been an inactive compara-
tor such as a placebo, low-dose psychedelic, or a non-
psychoactive pharmacological agent (e.g., niacin).
Outcomes
We included trials that used clinically validated scales for
depression or mood state outcomes. For depression symp-
toms, those scales were as follows: Hamilton Depression
Rating Scale (HAM-D), Montgomery–Åsberg Depression
Rating Scale (MADRS), Beck Depression Inventory (BDI),
and Hospital Anxiety and Depression Scale (HADS; specif-
ically, the depressive sub-score). To measure mood state, the
following scales were included: Adjective Mood Rating
Scale (AMRS; specifically anxiety-depressiveness sub-
score), Positive and Negative Affect Schedule (PANAS;
specifically negative score), Profile of Mood States
(POMS), and Persisting Effects Questionnaire (PEQ; specif-
ically negative mood).
Table 1 Search terms used in systematic review search
Participants
Human clinical trials involving patients with depression or healthy
volunteers
Interventions
Psychedelic* or Lysergic acid or LSD or Dimethyltryptamin* or DMT
or Ayahuasca or Hoasca or Psilocybin or Mescaline or Peyote.
Comparator
Random* or Trial or Intervention
Outcomes
Depression or Depressive Mood or Mental Illness or Mental Health or
Mental Disorder or Affective Disorder
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To provide temporal clarity of the psychedelic’s effects
(Carhart-Harris et al. 2016b), the outcomes of mood state
and depressive symptoms were categorized and analyzed with
respect to time-point collected after the respective dosing
session:
& Acute effects: outcomes from 3 h to 1 day after dosing
session.
& Medium-term effects: outcomes from 2 to 15 days after
dosing session.
& Long-term effects: outcomes from 16 to 60 days after
dosing session.
These time-points were selected because antidepressant
drugs commonly require approximately 2 weeks to initiate a
therapeutic response (Cipriani et al. 2018; Hengartner and
Plöderl 2018), while the psychotropic effects of substances
with psychedelic actions, for instance ketamine and classical
serotonergic psychedelics, commence within hours and have
been reported to last approximately 2 weeks (Corriger and
Pickering 2019; Sanacora et al. 2017).
We excluded data from studies with outcomes measured
within less than 3 h of receiving the psychedelic to avoid
assessment confounding from changes in cognition and per-
ception induced acutely by the substance. Furthermore, data
was also excluded from trials with data collected 60 days or
longer after the intervention due to the poor reliability of ret-
rospective data. Outcomes from the open-label phase of
double-blind studies were also not included. There was no
restriction based on sample size, the duration or severity of
symptoms, comorbid disorders, or participant demographics.
Quality assessment of included clinical trials
The quality of eligible clinical trials was assessed using the
Jadad scale (Jadad et al. 1996) completed by author NLGC
and cross-checked by WM and JS.
Data extraction and analysis
Effect size data of each experimental group was extracted and
converted to standardized mean differences (SMD) with 95%
confidence intervals (CIs). Data were initially extracted by
one author (NLGC), and then cross-checked independently
by an additional author (WM). In line with conventional in-
terpretations, SMD were classified as negligible (< 0.2), small
(0.2–0.4), moderate (0.4–0.8), or large (> 0.8) (Higgins and
Green 2011).
In cases where continuous outcomes were reported as
weighted mean differences or raw mean differences, these
were recalculated into an SMD (Hedges’ g) using
Comprehensive Meta-Analysis 3.0. Studies that reported the
outcomes by the following: (a) psychedelics dose (Hasler et al.
2004; Wittmann et al. 2007) and (b) separately for sessions
before and after cross-over (Griffiths et al. 2016; Griffiths
et al. 2006; Ross et al. 2016), each outcome having their data
combined and the mean of the SMD being used in analysis.
When there was more than one outcome, the effect sizes were
calculated for each one and then the averaged was used in the
meta-analysis (Higgins and Green 2011).
We also extracted the number of participants (N), along
with the number of trials/comparisons (K) from which the
pooled effect size was derived. Additionally, all analyses were
performed with a random-effect model, which considers both
between-study andwithin-study variability. The heterogeneity
was quantified using the I2 statistic, and categorized as low
(I2 < 25%), moderate (I2 = 25–50%), or high (I2 > 50%). Other
relevant study characteristics were also extracted, specifically
with regard to dose and if psychotherapy support was offered.
Sub-group or secondary analyses of clinical response with
respect to the type of psychedelic substance or population
(patients with a mood disorder or healthy volunteers) were
also undertaken. Safety and tolerability outcomes were not
included in the meta-analysis due to marked heterogeneity in
reporting. Instead, this information was extracted and narra-
tively reviewed. Although there is a recognized difficulty in
having appropriate blinding in studies with psychedelics, we
assumed for the calculation of the JADAD score that an ap-
propriate placebo could include substances that may induce
some similar physiological and/or cognitive effect of psyche-
delics, such as methylphenidate, niacin, or low doses of the
psychedelics. The potential impact of publication bias was
assessed using fail-safe N and Egger’s regression test of the
intercept. A statistically significant effect was regarded as a p
value of < 0.05. The data was analyzed and figures prepared
via Comprehensive Meta-Analysis 3.0.
Results
Systematic search results
The search returned 570 results, which was reduced to 565
after duplicates were removed. Title and abstract screening
removed 533 articles, while 32 manuscripts were retrieved
and reviewed in full. Of these, 14 were open-label clinical
trials and consequently were not included in this meta-
analysis (Bogenschutz et al. 2015; Carhart-Harris et al.
2018; Carhart-Harris et al. 2016a; Carhart-Harris et al. 2017;
Carhart-Harris et al. 2011; Kaelen et al. 2018; Lyons and
Carhart-Harris 2018a; Lyons and Carhart-Harris 2018b;
Osorio Fde et al. 2015; Roseman et al. 2017; Sanches et al.
2016; Stroud et al. 2018). From the 18 double-blind trials
selected, 6 were excluded because they did not meet the in-
clusion criteria. Specifically, 3 did not have a placebo-control
design (Daumann et al. 2008; Gouzoulis-Mayfrank et al.
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2005; Schmid and Liechti 2018); 1 clinical trial used micro-
doses of LSD (Bershad et al. 2019); 1 trial measured outcomes
only 2 h after treatment (Santos et al. 2007), and one clinical
trial showed unpublished outcomes collected after 60 days of
psychedelic dosing session (Griffiths et al. 2008). Thus, we
were left 12 studies which met the criteria for inclusion. For
the PRISMA flow diagram, see Fig. 1.
Description of studies
For study attributes involving type of participants, mood di-
agnosis, number of treatment session, psychedelic doses, and
placebo type, see Table 2. Of the 12 studies included, 8 used
psilocybin (Griffiths et al. 2016; Griffiths et al. 2006; Grob
et al. 2011; Hasler et al. 2004; Kometer et al. 2012;
Kraehenmann et al. 2015; Ross et al. 2016; Wittmann et al.
2007), 3 used LSD (Dolder et al. 2016; Gasser et al. 2014;
Schmid et al. 2015), and 1 usedDMT in the form of ayahuasca
(Palhano-Fontes et al. 2019). In summary, these involved 257
participants, made up of 124 healthy volunteers and 133 pa-
tients with mood disorders. All trials provided a single psy-
chedelic administration by dose, with exception of Gasser
et al. (2014), where LSD was administered twice.
All studies utilized a cross-over design, other than Palhano-
Fontes et al. (2019), which used a parallel design. Ross et al.
(2016), Gasser et al. (2014), Griffiths et al. (2006), and
Griffiths et al. (2016) also included psychotherapy to support
the psychedelic intervention. No clinical trials involving mes-
caline met the criteria for inclusion.
Quality assessment of the included meta-analyses
For methodological quality scores of all the clinical trials in-
cluded, see supplementary material Table S1. Two studies had
a maximum score of 5/5: Ross et al. (2016) (psilocybin) and
Palhano-Fontes et al. 2019 (ayahuasca). Of note, from 12
studies, only 2 trials described the randomization technique
used while only 7 detailed participant withdrawal. The main
issue related to studies quality was the blinding process. From
12 studies included, 3 did not present details regarding the
placebo condition used. However, for two of them, we were
able to obtain further information directly from the study au-
thors (Table S1).
Few studies analyzed the integrity of the blinding process
by questionnaires assessed in volunteers and/or via the re-
search team (Gasser et al. 2014; Griffiths et al. 2006;
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Fig. 1 PRISMA flow diagram of
systematic review and meta-
analysis of classic serotonergic
psychedelics for mood and de-
pressive symptoms
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Griffiths et al. 2016; Palhano-Fontes et al. 2019; Ross et al.
2016). Griffiths et al. (2006 and 2016), while Palhano-Fontes
et al. (2019) related success in the blinding process, whereas
Gasser et al. (2014) and Ross et al. (2016) did not appear to
achieve success in blindness despite the use as placebo a low
dose of psychedelic (LSD) and niacin, respectively.
Although the participant expectancy about the study is
not part of the JADAD scale, it is relevant to analyze as it
can play a significant role both in blinding and in partic-
ipants and evaluators responses. From 12 studies, 3 de-
tailed some strategies aiming to reduce these expectan-
cies, such as the use of instructional sets, multiples eval-
uators, naïve volunteers, individual, and not groups exper-
iments, parallel study designer (Griffiths et al. 2006;
Griffiths et al. 2016; Palhano-Fontes et al. 2019).
However, no studies used expectancy measures as a co-
factor in statistical analysis of clinical response.
Mood state and depressive symptom outcomes
Mood state
Meta-analyses were conducted on the measures of negative
mood state of healthy volunteers and also in patients with a
mood disorder, separately. Only one study was included in the
systematic review, analyzing medium-term mood changes;
therefore, it was not possible to undertake a meta-analysis
for this time-point (Grob et al. 2011).
Meta-analysis of acute measures of mood state, collected
between 3 h and 1 day after treatment, showed a moderate
clinical effect size of psychedelics in the reduction of negative
mood when compared to placebo in both healthy participants
(N = 103, K = 6, SMD = − 0.705, CIs − 0.987 to − 0.424,
p < 0.01; I2 = 2.1%) and patients with a mood disorder (N =
41, K = 2, SMD= − 0.632, CIs − 1.171 to − 0.092, p = 0.022;
I2 = 7.6%), with low variance across studies (Healthy volun-
teers: Dolder et al. 2016; Hasler et al. 2004; Kometer et al.
2012; Kraehenmann et al. 2015; Schmid et al. 2015;
Wittmann et al. 2007, patients: Grob et al. 2011; Ross et al.
2016) (Fig. 2 and supplementary material table S2). No study
was located providing data on acute mood state changes after
ayahuasca treatment.
Sub-analysis by psychedelic drug in healthy volunteers re-
vealed a highly significant effect with a moderate effect size
for both LSD (N = 32, K = 2, SMD= − 0.757, CIs − 1.203 to
− 0.311, p = 0.001; I2 = 5.2%) (Dolder et al. 2016; Schmid
et al. 2015) and psilocybin in negative mood reduction with
low variability across studies (N = 62, K = 4, SMD= − 0.671,
CIs − 1.034 to − 0.309, p < 0.001; I2 = 3.4%) (Hasler et al.
2004; Kometer et al. 2012; Kraehenmann et al. 2015;
Wittmann et al. 2007) (Fig. 2 and table S2).
Moreover, the meta-analysis of long-term measures of
mood state, between 16 and 60 days after treatment, showed
that psilocybin also had a moderate long-term effects in reduc-
tion of negative mood in patients with a mood disorder, with
low heterogeneity across trials (N = 110, K = 3, SMD = −
0.495, CIs − 0.829 to − 0.161, p = 0.004; I2 = 2.9%)
(Griffiths et al. 2006; Ross et al. 2016) (Table S2). No studies
examined long-term changes on mood state in healthy partic-
ipants, and after LSD or ayahuasca treatment.
Table 2 Study summary of clinical trials included in the meta-analysis
Study Design N Subject Psychedelic Dose Session# Placebo
Gasser et al. 2014 CO 12 A and LT LSD 200 μg 2 LSD 20 μg
Schmid et al. 2015 CO 16 Healthy LSD 200 μg 1 Mannitol**
Dolder et al. 2016 CO 16 Healthy LSD 100 μg 1 Mannitol**
Palhano-Fontes et al. 2019 P 29 TRD Ayahuasca 360 μg/kg 1 Zinc sulfate
Hasler et al. 2004 CO 8 Healthy Psilocybin &115, 215 and 315 μg/k 4 Lactose
Wittmann et al. 2007 CO 12 Healthy Psilocybin 115 and 250 μg/kg 2 Lactose
Griffiths et al. 2006 CO 30 Healthy Psilocybin 429 μg/kg 1 Methylphenidate
Kometer et al. 2012 CO 17 Healthy Psilocybin 215 μg/kg 1 Not specified
Kraehenmann et al. 2015 CO 25 Healthy Psilocybin 160 μg/kg 1 Lactose
Griffiths et al. 2016 CO 51 A, D and LT Psilocybin 314 and 429 μg/kg 1 P* 43 and 14 μg/kg
Ross et al. 2016 CO 29 A and LT Psilocybin 300 μg/kg 1 Niacin
Grob et al. 2011 CO 12 A and LT Psilocybin 200 μg/kg 1 Niacin
CO, cross-over;P, parallel;N, sample size;A, anxiety;D, depression; TRD, treatment-resistant depression; LT, life-threatening illness; LSD, lysergic acid
diethylamide, P*, psilocybin
#Number of psychedelic sessions during the trial
& Low dose of 45 mg/kg of psilocybin was not included in the meta-analysis
** Information provided by the author, it does not have in the manuscript
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Depressive symptoms
Three meta-analyses were conducted with measures of de-
pressive symptoms assessed by depression symptom rating
scales from patients with a mood disorder: acute effects, me-
dium-term, and longer-term clinical effects.
Themeta-analysis of acute effects (between 3 h and 1 day) on
depressive symptoms showed a significant and moderate clini-
cal effect size of psychedelics (psilocybin and ayahuasca) for
reduction of depressive symptoms. Again, low heterogeneity
was observed across studies (N = 70, K = 3, SMD= − 0.720,
CIs − 1.189 to − 0.251, p = 0.003; I2 = 5.7%) (Grob et al.
2011; Palhano-Fontes et al. 2019; Ross et al. 2016) (Fig. 3 and
table S2). A sub-analysis of the individual psychedelics revealed
that psilocybin had a significant andmoderate clinical effect size
on the reduction of depressive symptoms in patients with
a mood disorder, with low variance across studies (N = 41,
K = 2, SMD= − 0.665, CIs − 1.262 to − 0.048, p = 0.034; I2 =
9.6%) (Grob et al. 2011; Ross et al. 2016) (Fig. 3 and table S2).
There were no clinical trials located involving the acute assess-
ment of LSD’s effects on depressive symptoms.
We found a significant and large effect of classic psyche-
delics (psilocybin and ayahuasca) in the medium-term assess-
ment of depressive symptoms, with low heterogeneity across
studies (N = 70, K = 3, SMD = − 0.841, CIs − 1.359 to −
0.323, p = 0.001; I2 = 7.0%) (Grob et al. 2011; Palhano-
Fontes et al. 2019; Ross et al. 2016) (Fig. 3 and table S2).
However, a secondary analysis of psilocybin studies showed
a marginally non-significant effect for reduction of depression
between 7 and 15 days after treatment (N = 41, K = 2, SMD=
− 0.666, CIs − 1.374 to − 0.042, p = 0.065; I2 = 13%) (Grob
et al. 2011; Ross et al. 2016) (Fig. 3 and table S2). We can
note that the medium-term clinical effects of classic psyche-
delics on depressive symptoms were mainly driven by data
from the ayahuasca study.
The assessment of the longer-term (16 to 60 days) effect of
psychedelics on the reduction of depressive symptoms revealed a
highly significant effect with a moderate to large effect size (N =
92, K = 3, SMD= − 0.792, CIs − 1.222 to − 0.362, p < 0.001;
I2 = 4.8%) (Gasser et al. 2014; Griffiths et al. 2006; Ross et al.
2016) (Fig. 3 and table S2). The sub-analysis of psilocybin trials
only also showed a large clinical effect in the reduction of de-
pressive symptoms in patients with mood disorders, with low
heterogeneity between studies (N = 80, K = 2, SMD= − 0.826,
CIs − 1.285 to − 0.367, p < 0.001; I2 = 5.5%) (Griffiths et al.
2016; Ross et al. 2016) (Fig. 3 and table S2).
Safety and tolerability
From the 12 studies included, 3 did not detail data pertaining
to safety or tolerability of the psychedelic used (Kometer et al.
2012; Kraehenmann et al. 2015; Wittmann et al. 2007). In
Study Psychedelic Subject Outcome Statistic for each study
SMD SE I2 l-CI u-CI Z p
Dolder et al. (2016) LSD H AMRS (1d) -0.898 0.298 8.9 -1.482 -0.313 -3.009 0.003
Schmid et al. (2015) LSD H AMRS (1d) -0.561 0.352 12.4 -1.251 0.128 -1.596 0.111
LSD H -0.757 0.228 5.2 -1.203 -0.311 -3.327 0.001
Hasler et al. (2004) Psilocybin H AMRS (c) -0.344 0.477 22.7 -1.278 0.590 -0.721 0.471
Kometer et al. (2012) Psilocybin H PANAS (3h) -0.945 0.354 12.5 -1.639 -0.251 -2.669 0.008
Kraehenmann et al. (2015) Psilocybin H PANAS (3.5h) -0.799 0.308 9.5 -1.403 -0.195 -2.593 0.010
Wittmann et al. (2007) Psilocybin H AMRS (4.5h) -0.343 0.397 15.8 -1.121 0.436 -0.863 0.388
Psilocybin H -0.671 0.185 3.4 -1.034 -0.309 -3.632 0.000
Combined H -0.705 0.143 2.1 -0.987 -0.424 -4.916 0.000
Grob et al. (2011) Psilocybin P POMS (c) -0.539 0.408 16.6 -1.338 0.260 -1.322 0.186
Ross et al. (2016) Psilocybin P POMS (1d) -0.709 0.373 13.9 -1.440 0.022 -1.901 0.057
Psilocybin P -0.632 0.275 7.6 -1.171 -0.092 -2.295 0.022
-2.00 -1.00 00 1.00 2.00
Psychedelic Placebo
Hedges's g and 95% CI 
Acute Effects of Psychedelics for Negative Mood State
Fig. 2 The effect size (SMD) of acute clinical effects of classic seroto-
nergic psychedelic and placebo treatments on negative mood state in
healthy volunteers and patients with mood disorders, shown as Hedges’
g with 95% confidence interval. Negative Hedges’ g indicates favor of
psychedelics. Squares represent study effect sizes; open diamonds repre-
sent effect sizes of sub-group analyses by drug (lysergic acid
diethylamide [LSD] or psilocybin); closed diamonds represent overall
effect sizes for healthy volunteers (H) or mood disorder patients (P).
The sizes of squares and diamonds are proportional to the SMD.
Combined: polled LSD and psilocybin. d: day and h: hours. (c) The
following instruments were grouped and the mean of SMD was used in
analysis: Grob et al. (2011), Profile of Mood States (POMS) of 6 h and
1 day. Hasler et al. (2004), Adjective Mood Rating Scale (AMRS) of
4.5 h and 1 day. PANAS: Positive and Negative Affect. SE, standard
error; l-IC, low confidence interval; u-CI, up confidence interval; I2, het-
erogeneity across studies (%); Z, z value; p, p value
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general, the other clinical trials reported that classic serotoner-
gic psychedelics were well-tolerated. Acute psychological
side-effects induced by psychedelics in the included studies
were mainly mild anxiety episodes, tearing/crying, nausea,
vomit, headache, and slight sympathomimetic effect, such as
increase in blood pressure, heart rate, and pupil size, and rare
episodes of paranoia was related. No study participants were
noted as requiring pharmacological intervention to address
these side-effects. Long-term studies did not indicate any per-
sistent anxiety, suicidal crisis, or psychotic state.
Publication bias
With concern of publication bias, the fail-safe N of this meta-
analysis is 114 (N = 12, Z = − 6.339, p < 0.001). There would
need to be 9.5 missing studies for every observed study for the
effect to be nullified. Egger’s regression test of the intercept also
did not report publication bias (B0 = − 0.191, IC = − 2.541 to
2.158, t = 0. 181, df = 10, 1-tailed p = 0.429). For the funnel
plot of publication bias, see supplementary material figure S1.
Discussion
This meta-analysis combined and evaluated data from 12
double-blind RCTs investigating the efficacy of classic sero-
tonergic psychedelics on mood state and depressive symp-
toms, between 3 h and 60 days after administration, in patients
with mood disorders, and healthy volunteers, separately. We
observed a significant moderate effect size for reduction of
acute negative mood outcomes in healthy volunteers, com-
pared to placebo, as well as significant moderate effects sizes
Medium-term Effects
Palhano-Fontes et al. (2018) Ayahuasca P C (2,7d) -1.042 0.388 15 -1.802 -0.283 -2.690 0.007
Ayahuasca P -1.042 0.388 15 -1.802 -0.283 -2.690 0.007
Grob et al. (2011) Psilocybin P BDI (15d) -0.302 0.397 15.7 -1.079 0.475 -0.762 0.446
Ross et al. (2016) Psilocybin P C (15d) -1.024 0.392 15.3 -1.792 -0.256 -2.615 0.009
Psilocybin P -0.666 0.361 13 -1.374 0.042 -1.844 0.065
Combined P -0.841 0.264 7 -1.359 -0.323 -3.183 0.001
Study Psychedelic Subject Outcome Statistic for each study
SMD SE I2 l-CI u-CI Z p
Acute Effects
Palhano-Fontes et al. (2018) Ayahuasca P MADRS (1d) -0.816 0.377 14.2 -1.555 -0.078 -2.167 0.030
Ayahuasca P -0.816 0.377 14.2 -1.555 -0.078 -2.167 0.030
Grob et al. (2011) Psilocybin P BDI (1d) -0.354 0.397 15.8 -1.133 0.425 -0.891 0.373
Ross et al. (2016) Psilocybin P C (1d) -0.974 0.411 16.9 -1.779 -0.168 -2.370 0.018
Psilocybin P -0.655 0.310 9.6 -1.262 -0.048 -2.115 0.034
Combined P -0.720 0.239 5.7 -1.189 -0.251 -3.010 0.003
Long-term Effects
Gasser et al. (2014) LSD P HADS (60d) -0.546 0.630 3.97 -1.780 0.698 -0.867 0.368
LSD P -0.546 0.630 3.97 -1.780 0.698 -0.867 0.368
Griffiths et al. (2016) Psilocybin P C (35d) -0774 0.287 8.2 -1.336 -0.212 -2.701 0.007
Ross et al. (2016) Psilocybin P C (42,49d) -0.930 0.406 16.5 -1.725 -0.135 -2.292 0.022
Psilocybin P -0.826 0.234 5.5 -1.285 -0.367 -3.528 0.000
Combined* P -0.792 0.219 4.8 -1.222 -0.362 -3.609 0.000
Effects of Psychedelics on Depressive Symptoms
-2.00 -1.00 00 1.00 2.00
Psychedelic Placebo
Hedges's g and 95% CI 
Fig. 3 Effect size (SMD) of acute, medium-term, and long-term clinical
effects of classic serotonergic psychedelics vs placebo treatments on de-
pressive symptoms of patients with mood disorders (P), shown as
Hedges’ g with 95% confidence interval. A negative Hedges’ g indicates
favor of psychedelics. Squares represent study effect sizes; open dia-
monds represent effect sizes of sub-group analyses by drug (psilocybin,
lysergic acid diethylamide [LSD], and ayahuasca); closed diamonds rep-
resent overall effect sizes of each time-point (acute, medium term, and
long term). The sizes of squares and diamonds are proportional to the
SMD. Combined: pooled ayahuasca and psilocybin. Combined*: pooled
LSD and psilocybin. d: day and h: hours. C: The score of the following
instruments were grouped and the mean of SMDwas used in analysis, for
Ross et al. (2016) and Griffiths et al. (2016), Beck Depression Inventory
(BDI) and Hospital Anxiety and Depression Scale (HADS); Palhano-
Fontes et al. (2019), Hamilton Depression Rating Scale and
Montgomery–Åsberg Depression Rating Scale (MADRS). SE, standard
error; l-IC, low confidence interval; u-CI, up confidence interval; I2, het-
erogeneity across studies (%); Z, z value; p, p value
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for acute and long-term reductions of negative mood state in
patients with mood disorders. For depressive symptoms, a
significant large effect size was detected from a medium-
term assessment, and a moderate effect size for both acute
and long-term outcomes was observed for patients, compared
to placebo.
Trials that assessed mood state response to psychedelics were
in general conducted in healthy volunteers and mainly assessed
acute outcomes. In this context, secondary analysis by psyche-
delic drug revealed moderate effect sizes for both psilocybin and
LSD, with a slightly larger effect size for LSD. A significant
moderate effect size in studies assessing the acute reduction of
negative mood also was observed to patients in psilocybin trials.
An analysis of longer-term data (16–60 days after treat-
ment) indicated that psilocybin maintains its response on
negative mood reduction of patients, with a moderate effect
size compared to placebo. In this meta-analysis, it was not
possible to undertake a meta-analysis for medium-term
mood changes due to insufficient clinical trials.
It is important study the effects of classic psychedelics in
both healthy volunteers and those with diagnosed mood dis-
orders because as their neurobiology is distinct, and the psy-
chobiological responses to drugs can be different between
these populations (Galvão et al. 2018). It is essential to under-
stand if any mood-elevating effects are evident in healthy
participants, and to be able to compare this with the response
of those with clinical depression. For note, it is usual that
clinical trials select only one of these groups, with few studies
assessing parallels groups of patients and healthy controls (de
Almeida et al. 2019; Galvão et al. 2018; Galvão-Coelho et al.
2020). This meta-analysis provides a data analysis of negative
mood in both healthy participants and patients with mood
disorders, to differentially assess both populations.
The larger effect size of LSD in acute reductions of negative
mood, in comparison to psilocybin, may be due to differing
pharmacokinetic profiles (Libânio Osorio Marta 2019). While
the onset of psychedelic effects is typically faster with psilocy-
bin, around 30 min vs 1 h for LSD, the total duration of psilo-
cybin acute effects are substantially shorter, at around 3.5 h,
compared with 8 to 12 h for LSD, depending on dose (Araujo
et al. 2015; Dolder et al. 2017). However, pharmacokinetic data
in this area remains limited. Besides classic serotonergic psy-
chedelics, few double-blinded, placebo-controlled clinical trials
have aimed to analyze acute mood changes in response to sub-
stances with psychedelic action (Krystal et al. 2006; Micallef
et al. 2003). Furthermore, positive results for ketamine treat-
ment in reduction of negative mood are for example observed
1 day after its administration, when compared with midazolam
treatment (Grunebaum et al. 2018).
Psychedelics, specifically psilocybin and ayahuasca, demon-
strated a moderate effect size in the acute reduction of depres-
sive symptoms compared to placebo. The fast onset of thera-
peutic response is a key characteristic of new potential “fast-
acting antidepressants,” which aside from classic psychedelics
also may include ketamine (Corriger and Pickering 2019; Ly
et al. 2018). Animal models reveal that the biological therapeu-
tic actions of antidepressants may in part be mediated via in-
creased neuroplasticity through the expression of brain-derived
neurotropic factor (BDNF) and its tyrosine kinase receptors
type B in the prefrontal cortex and hippocampus (Mannari
et al. 2008; Pilar-Cuéllar et al. 2012). Therefore, the delay in
the therapeutic onset may potentially correlate with the time
required for the elevation of the BDNF (Jesulola et al. 2018).
While fast-acting antidepressants also induce neuroplasticity by
BDNF increases, both in vitro and in vivo, this occurs through a
pathway different and faster than that of antidepressants, in-
volving the mammalian target of rapamycin (Ly et al. 2018).
Moreover, it has been suggested that substances with psyche-
delic effect are able to reframe negative memories, which is in
contrast to standard antidepressant pharmacotherapy in which
new information is processed with a positive bias (Harmer et al.
2017; Kometer et al. 2012).
The present meta-analysis also revealed a large effect size of
psychedelics (psilocybin, LSD, and ayahuasca) compared to
placebo, in the reduction of depressive symptoms in medium-
term investigations, that is, between 2 and 15 days after treat-
ment, which was evident from the ayahuasca study. Amoderate
effect size was seen for other psychedelics (LSD and psilocy-
bin) in the longer-term analysis (between 16 and 60 days after
interventions). Though it should be noted that this was due to
the assessment time-points employed, and not necessarily to do
with the length of ongoing antidepressant effect, another agent
with a shorter alacrity of response than standard antidepres-
sants, ketamine, suggests a similar temporal effects profile, with
the strongest responses occurring between 1 and 2 weeks post-
treatment (Corriger and Pickering 2019; Sanacora et al. 2017).
Furthermore, a recent meta-analysis showed stronger effect
sizes of classic psychedelics in reduction of depressive symp-
toms on days 7 and 21 after treatment comparing with baseline
scores (Romeo et al. 2020).
Sub-analysis of trials using psilocybin with patients with a
mood disorder and life-threatening disease identified moder-
ate acute and large long-term effects of this substance in the
reduction of depressive symptoms, when compared to place-
bo. These results are highly encouraging of further research
with this group, as a recent meta-analysis of the use of antide-
pressants for cancer patients reported no indication of effects
superior to placebo (Ostuzzi et al. 2018). The use of psyche-
delics in this population may extend beyond addressing affec-
tive symptoms, having a potentially specialized role in
assisting with existential psychological distress involving
mortality. However, it is important to highlight that mood
disorders in these patients are often a comorbidity of the life-
threatening disease, and the depressive symptoms can be
expressed in different ways for instance from the depressive
patients where the depression is the main pathology.
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Although anxiety symptoms are often present in mood dis-
orders, from 12 selected studies in systematic review, only 6
measured anxiety, and due the heterogeneity of these studies,
it was not possible to conduct a meta-analysis with them
(LSD, Gasser et al. 2014; Psylocibin; Grob et al. 2011;
Kometer et al. 2012; Kraehenmann et al. 2015; Ross et al.
2016; Griffiths et al. 2016). However, it is important to high-
light the importance of conducting this analysis when the data
becomes available.
An additionally important point in this context is the use of
“psychotherapy-assisted” applications of psychedelics. This
approach may not only be safer (andmore ethical); it may also
provide a potentially stronger therapeutic effect. The
psychedelic-assisted therapy, analyzed by studies that used
MDMA and classic psychedelics, showed stronger clinical
improvement of different mood and anxiety disorder than pla-
cebo (Luoma et al. 2020). This would however in the future be
advised to be assessed via controlled research comparing psy-
chedelic interventions alone and in combination with psycho-
logical assistance to determine if any additive or synergistic
effect was evident. Moreover, such comparison would deter-
mine whether either intervention provides better management
of any psychological distress which may emerge during con-
sumption of the psychedelic.
It is also important to note that despite the low number of
studies included in meta-analysis, low statistical heterogeneity
was observed across clinical trials and no publication bias was
detected. Moreover, in general, the included clinical trials indi-
cated that classic serotonergic psychedelics are well-tolerated,
although more reporting precision on adverse effects and longer
safety follow-ups are recommended in future studies. Acute
psychological and psychological side-effects were mainly mild
anxiety episodes and sympathomimetic effects, such as in-
creases in blood pressure, heart rate, and pupil size, which were
short-lived and did not require pharmacological intervention.
There are several critical challenges recognized in
conducting robust double-blind studies involving psyche-
delics. As revealed in our assessment of the methodological
quality of the studies reviewed, a significant issue was evident
regarding the presence of adequate blinding. In particular,
some studies did not report any details regarding the placebo
used, while others used a placebo which may or may not have
active effects. To address the issue of sufficient blinding, some
trials have used “active” placebos, such as low doses of psy-
chedelics or methylphenidate and niacin, which can induce
mild physiologic and cognitive changes. This is a well-
needed methodological advancement; however, some studies
still find issues in blinding process even after this approach.
Therefore, we must consider that unblinding is, at least in part,
responsible for the magnitude of the effect size provided in
this meta-analysis. Moreover, the expectancy of participants
and evaluators about the treatment can also modulate the
results. Despite 3 studies detailing strategies to deal with this
potential expectation, none included expectancymeasures as a
covariate in statistical analysis of clinical response, and this
should be considered in future studies.
Another issue of concern is the conducting of trials with
multiple sessions of psychedelics or cross-over designs. Most
included studies in this review used a cross-over study design,
introducing possible limitations related to potential carry-over
effects, as this raises the chance of the first session experience
increasing the expectation bias of next session (or resulting in a
carry-over effect if the active intervention is firstly used).
Moreover, how the data analysis is communicated in cross-
over studies should be better considered by the researchers.
For instance, separate analyses of the first and second cross-
over treatment administered, rather than having these both re-
sults analyzed together, are potentially a clearer method.
Additionally, some included clinical trials did not provide ade-
quate detail about the randomization strategy used and how
participant withdrawals were handled in the analysis, making
risk of bias assessment for these domains difficult. Further stud-
ies in this area are recommended to ensure adequate reporting
of randomization procedures in line with international reporting
guidelines (Higgins and Green 2011). Other limitations should
also be taken in account in this meta-analysis: the small sample
sizes of the included studies, the high heterogeneity in study
design and population, multiple psychedelic doses, variety of
outcome scales used, and different time-points assessed. For the
last point, we acknowledge that analyzing the long-term effects
may not entirely be methodologically sound due to the long
duration between substance use and data collection.
Therefore, future studies should consider these aspects with
the aim of improving the quality of trials (Johnson et al. 2008).
In summation, methodological weaknesses aside, our
meta-analysis provides encouraging evidence for the potential
use of classic serotonergic psychedelics in the reduction of
both negative mood state and depressive symptoms. While
there are currently limited studies that have investigated some
of these agents (in particular ayahuasca), the promising results
of this review support the need for ongoing and more robust
research in this emerging field to further explore the effect of
psychedelics in adults with depression.
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